Medtronic PLC

NYSE MDT

Download Data

Medtronic PLC Revenue Per Share for the year ending April 30, 2024: USD 24.33

Medtronic PLC Revenue Per Share is USD 24.33 for the year ending April 30, 2024, a 3.84% change year over year. Revenue per share measures the amount of revenue generated by a company per outstanding share. It is calculated by dividing the revenue by the number of outstanding shares (weighted average). This ratio provides insights into the company's revenue generation on a per-share basis. A higher revenue per share indicates stronger revenue performance and potentially higher value per share for investors.
  • Medtronic PLC Revenue Per Share for the year ending April 30, 2023 was USD 23.43, a -0.07% change year over year.
  • Medtronic PLC Revenue Per Share for the year ending April 30, 2022 was USD 23.45, a 5.41% change year over year.
  • Medtronic PLC Revenue Per Share for the year ending April 30, 2021 was USD 22.24, a 3.94% change year over year.
  • Medtronic PLC Revenue Per Share for the year ending April 30, 2020 was USD 21.40, a -4.93% change year over year.
NYSE: MDT

Medtronic PLC

CEO Mr. Geoffrey Straub Martha
IPO Date Jan. 13, 1978
Location Ireland
Headquarters 20 On Hatch, Dublin, Ireland, 2
Employees 95,000
Sector Healthcare
Industry Medical devices
Description

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Similar companies

ABT

Abbott Laboratories

USD 102.87

0.67%

StockViz Staff

September 8, 2024

Any question? Send us an email